Adamis Pharmaceuticals (ADMP) Stock Price, News & Analysis

Company Overview

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.77 to $3.99
• 52-Week Range: N/A
• Volume: 119,800 shs
• Average Volume: 811,695 shs
• Market Capitalization: $7.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ADMP Stock Analysis - Frequently Asked Questions

How were Adamis Pharmaceuticals' earnings last quarter?

Adamis Pharmaceuticals Co. (NASDAQ:ADMP) issued its quarterly earnings results on Thursday, March, 31st. The specialty pharmaceutical company reported ($4.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.80) by $1.40. Adamis Pharmaceuticals had a negative net margin of 502.73% and a negative trailing twelve-month return on equity of 420.53%.

When did Adamis Pharmaceuticals' stock split?

Adamis Pharmaceuticals's stock reverse split before market open on Monday, May 22nd 2023. The 1-70 reverse split was announced on Monday, May 22nd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of Adamis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adamis Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Aurinia Pharmaceuticals (AUPH), Corbus Pharmaceuticals (CRBP) and FuelCell Energy (FCEL).

Company Calendar

• Last Earnings: 3/31/2022
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ADMP
• CUSIP: N/A
• CIK: 887247
• Web: www.adamispharmaceuticals.com
• Phone: (858) 997-2400
• Fax: N/A
• Employees: 11
• Year Founded: 2006

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-26,480,000.00
• Net Margins: -502.73%
• Pretax Margin: -471.80%
• Return on Equity: -420.53%
• Return on Assets: -256.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.23
• Quick Ratio: 0.19

Sales & Book Value

• Annual Sales: $4.76 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.26) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 9,360,000
• Free Float: 9,237,000
• Market Cap: $7.26 million
• Optionable: Optionable
• Beta: 1.27